Group 1: Suspension - Hengwei Technology plans to acquire 75% of Shanghai Shuhang Information Technology, leading to a stock suspension. The target company is a prominent provider of enterprise-level scenario-based AI solutions [1] Group 2: Private Placement - Defu Technology intends to raise no more than 1.93 billion yuan for the acquisition of 100% equity in Luxembourg Copper Foil and for electronic chemical projects related to copper foil additives [2] Group 3: Shareholding Increase - Luxshare Precision's actual controller and vice chairman Wang Laisheng has completed an increase in shareholding, with a total investment of 200 million yuan [3] Group 4: External Investment and Daily Operations - Luxiao Technology's subsidiary plans to launch a home-based AI service robot, aiming to sell no less than 1 million units of various products in the US and European markets by 2026-2028 [4] - Haon Automotive received approximately 2.477 billion yuan in designated contracts for global automotive brand ADAS perception systems and AK2 radar systems [5] - China Shipbuilding Technology signed a green methanol sales contract worth about 40 million USD per year, expected to commence supply after the company's wind power methanol project is operational [6] - Fuyuan Pharmaceutical's Pioglitazone Metformin tablets (15mg/850mg) have obtained a drug registration certificate [7] - Hendi Pharmaceutical received approval notification for the listing application of Methoxychloropramine hydrochloride chemical raw materials [8] - Vanke A received a loan of no more than 2.064 billion yuan from Shenzhen Metro Group [9] - An彩高科 plans to acquire 100% equity of Henan High Purity Minerals for 120,000 yuan [10] - Huajin Technology has submitted an application for the issuance and listing of overseas listed shares (H shares) to the Hong Kong Stock Exchange [11] - Digital Vision plans to sell no more than 5% of its shares in Bohui Technology [12] Group 5: Performance Changes - Brothers Technology expects a net profit of 100 million to 115 million yuan for the first three quarters, representing a year-on-year increase of 207.32% to 253.42%, driven by rising prices of certain vitamin products and increased capacity utilization and sales of the phenol project [13]

福元医药公告，近日，公司收到了国家药品监督管理局颁发的吡格列酮二甲双胍片（15mg/850mg） （规格：每片含盐酸吡格列酮15mg（以C₁₉H₂₀N₂O₃S计）和盐酸二甲双胍850mg）《药品注册证书》 （证书编号：2025S02764），批准该药品生产。 ...